Inventor · disambiguated record
Naxin Tu
Also filed as: TU NAXIN
33 granted patents·17 pending applications·232 citations·filing 2010–2025
97Inventor score
Top patents by PatentIndex Score
50 records- 0198US9113616B2Genetically modified mice having humanized TCR variable genesREGENERON PHARMA·Filed 2012·Granted Aug 25, 2015·67 cites·42 claims
- 0298US9043996B2Genetically modified major histocompatibility complex animalsREGENERON PHARMA·Filed 2013·Granted Jun 2, 2015·31 cites·42 claims
- 0398US8847005B2Genetically modified major histocompatibility complex miceREGENERON PHARMA·Filed 2012·Granted Sep 30, 2014·33 cites·16 claims
- 0496US10542735B2Humanized non-human animals with restricted immunoglobulin heavy chain lociREGENERON PHARMA·Filed 2018·Granted Jan 28, 2020·6 cites·26 claims
- 0595US9687566B2Low affinity FCGR deficient miceREGENERON PHARMA·Filed 2015·Granted Jun 27, 2017·6 cites·15 claims
- 0695US9056130B2Humanized Fc gamma R miceREGENERON PHARMA·Filed 2014·Granted Jun 16, 2015·9 cites·13 claims
- 0794US10426848B2Humanized FcγR miceREGENERON PHARMA·Filed 2017·Granted Oct 1, 2019·3 cites·16 claims
- 0894US9089599B2Low affinity FCGR deficient miceREGENERON PHARMA·Filed 2014·Granted Jul 28, 2015·9 cites·6 claims
- 0993US9474255B2Non-human animals having humanized Fc-gamma receptorsREGENERON PHARMA·Filed 2015·Granted Oct 25, 2016·6 cites·21 claims
- 1093US9221894B2Isolated cells from humanized FcγR miceREGENERON PHARMA·Filed 2014·Granted Dec 29, 2015·9 cites·15 claims
- 1192US9585373B2Genetically modified major histocompatibility complex miceREGENERON PHARMA·Filed 2014·Granted Mar 7, 2017·8 cites·10 claims
- 1292US8658154B2Humanized FcγR miceMACDONALD LYNN·Filed 2010·Granted Feb 25, 2014·9 cites·15 claims
- 1392US2024424145A1LOW AFFINITY FcyR DEFICIENT MICEREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1491US11020495B2Humanized low affinity FCγR mouse cellsREGENERON PHARMA·Filed 2019·Granted Jun 1, 2021·2 cites·33 claims
- 1591US8658853B2Low affinity FcγR deficient miceMACDONALD LYNN·Filed 2012·Granted Feb 25, 2014·7 cites·9 claims
- 1690US9848587B2Humanized T cell co-receptor miceREGENERON PHARMA·Filed 2014·Granted Dec 26, 2017·6 cites·28 claims
- 1788US10820582B2Non-human animals having an engineered immunoglobulin Λ light chain locusREGENERON PHARMA·Filed 2017·Granted Nov 3, 2020·3 cites·21 claims
- 1888US8883496B2Humanized FcgR miceMACDONALD LYNN·Filed 2011·Granted Nov 11, 2014·9 cites·11 claims
- 1988US2024365761A1Genetically modified major histocompatibility complex miceREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2087US2025000070A1Humanized t cell co-receptor miceREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2184US10986822B2Genetically modified major histocompatibility complex miceREGENERON PHARMA·Filed 2019·Granted Apr 27, 2021·1 cites·19 claims
- 2283US11528895B2Genetically modified T cell receptor miceREGENERON PHARMA·Filed 2015·Granted Dec 20, 2022·2 cites·19 claims
- 2382US11219195B2Genetically modified major histocompatibility complex miceREGENERON PHARMA·Filed 2019·Granted Jan 11, 2022·1 cites·9 claims
- 2482US10820581B2Humanized T cell co-receptor miceREGENERON PHARMA·Filed 2017·Granted Nov 3, 2020·1 cites·24 claims
- 2581US10219493B2Genetically modified major histocompatibility complex miceREGENERON PHARMA·Filed 2017·Granted Mar 5, 2019·1 cites·10 claims
- 2680US12036288B2Methods of using humanized FCγR mice to assay Fc regionsREGENERON PHARMA·Filed 2021·Granted Jul 16, 2024·0 cites·19 claims
- 2779US11576984B2Genetically modified mouse with humanized immunoglobulin heavy chain constant region genes and method of usingREGENERON PHARMA·Filed 2019·Granted Feb 14, 2023·1 cites·20 claims
- 2879US10555507B2Non-human animals having humanized Fc-gamma receptorsREGENERON PHARMA·Filed 2016·Granted Feb 11, 2020·1 cites·22 claims
- 2979US2023232795A1Non-human animals having humanized fc-gamma receptorsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 3078US2022386575A1Genetically modified t cell receptor miceREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 3175US2021195878A1Genetically modified major histocompatibility complex miceREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 3274US12063915B2Humanized T cell co-receptor miceREGENERON PHARMA·Filed 2020·Granted Aug 20, 2024·0 cites·29 claims
- 3373US11503812B2Non-human animals having humanized Fc-gamma receptorsREGENERON PHARMA·Filed 2019·Granted Nov 22, 2022·0 cites·11 claims
- 3473US2025302017A1Genetically modified mice comprising humanized cellular immune system components with improved diversity of tcrb repertoireREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 3573US2025386808A1Non-human animals expressing exogenous terminal deoxynucleotidyltransferaseREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 3671US12295354B2Non-human animals expressing exogenous terminal deoxynucleotidyltransferaseREGENERON PHARMA·Filed 2021·Granted May 13, 2025·0 cites·19 claims
- 3771US9700025B2Genetically modified major histocompatibility complex animalsREGENERON PHARMA·Filed 2015·Granted Jul 11, 2017·1 cites·13 claims
- 3871US2023277692A1Humanized rodents for testing therapeutic agentsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 3970US12376573B2Genetically modified mice comprising humanized cellular immune system components with improved diversity of TCRB repertoireREGENERON PHARMA·Filed 2022·Granted Aug 5, 2025·0 cites·23 claims
- 4068US12433264B2Non-human animals having an engineered immunoglobulin lambda light chain locusREGENERON PHARMA·Filed 2020·Granted Oct 7, 2025·0 cites·21 claims
- 4167US2022033847A1Non-human animals expressing humanized c1q complexREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 4265US2024102045A1Vectors, genetically modified cells, and genetically modified non-human animals comprising the sameREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 4364US2024099279A1Genetically modified mice expressing components of human cellular immune systemREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 4463US11186848B2Non-human animals expressing humanized C1Q complexREGENERON PHARMA·Filed 2018·Granted Nov 30, 2021·0 cites·25 claims
- 4563US10980221B2Non-human animals expressing exogenous terminal deoxynucleotidyltransferaseREGENERON PHARMA·Filed 2017·Granted Apr 20, 2021·0 cites·21 claims
- 4658US2017273286A1Genetically Modified Major Histocompatibility Complex AnimalsREGENERON PHARMA·Filed 2017·Application pending·0 cites
- 4757US2024065239A1Mice expressing humanized fc alpha receptorsREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 4852US2023172170A1Non-human animals having a humanized cxcl13 geneREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 4947US2025255282A1Vectors, genetically modified cells, and genetically modified non-human animals comprising the sameREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 5046US2016081314A1Chimeric Antigen ReceptorsREGENERON PHARMA·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Naxin Tu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →